Browsing by Author "Levin, A. I."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Lipid emulsion therapy : non-nutritive uses of lipid emulsions in anaesthesia and intensive care
    (Medpharm Publications, 2015) Buysa, M.; Scheepers, P. A.; Levin, A. I.
    ENGLISH ABSTRACT: Lipid emulsions were introduced into clinical practice more than five decades ago as a calorically dense, non-glucose-based energy source for parenteral nutrition. Recently, intravenous lipid emulsions have been used as rescue for systemic local anaesthetic toxicity. However, the non-nutritive, therapeutic roles of lipid emulsions have recently expanded. This review considers these newer uses of lipid emulsions as drug administration vehicles, for treatment of lipophilic drug toxicity, and as modifiers of ischaemia-reperfusion injury in the anaesthetic and critical care environments. The potential adverse effects of lipid emulsion administration are also succinctly addressed.
  • Thumbnail Image
    Item
    Xylocaine® 10% pump spray as topical anaesthetic for venepuncture pain
    (Taylor & Francis Group, 2018) Van Straten, A.; Murray, A. A.; Levin, A. I.
    Background: Cutaneous analgesia for venepuncture pain can be achieved using various topically applied local anaesthetic formulations. Xylocaine® 10% Pump Spray containing lignocaine hydrochloride and 95% ethanol is exclusively recommended for mucosal anaesthesia. However, this formulation is readily able to penetrate skin. This study investigated whether topical pre-treatment with Xylocaine® 10% Pump Spray could facilitate analgesia for venepuncture. Methods: A single-centre, prospective, randomised, double-blind placebo-controlled trial was conducted. One hundred patients were enrolled. The control and intervention groups had 0.5 ml saline and 0.5 ml Xylocaine® applied for 20 min to preselected venepuncture sites. Pain associated with an 18-gauge cannula venepuncture was rated on an 11-point Numerical Rating Scale. A two-point or 30% reduction in pain would be deemed clinically significant. Results: Pain scores were lower (p = 0.001) in the Xylocaine® (median 2; 95% CI 2–3) than the saline (median 4; 95% CI 3–5) group. Moderate-to-severe pain occurred in fewer Xylocaine® (18%) than saline (42%) treated patients (relative risk 0.43, CI 0.22 to 0.48; NNT = 5). Conclusion: Topical Xylocaine® 10% Pump Spray pre-treatment provided a time-effective method of reducing venepuncture-associated pain.